Sirtris Pharmaceuticals to Present at Think Equity Conference September 13th, 2006

Cambridge, MA –September 7th, 2006 -- Sirtris Pharmaceuticals, the leading sirtuin therapeutics company, announced today that it will be presenting at the Think Equity Conference in San Francisco, CA. Sirtris will discuss the Company’s strategy for discovering and developing first in class therapeutics that modulate sirtuins, a recently discovered family of enzymes that promote healthy cellular function. The presentation will be delivered at 2:30 PST on Wednesday, September 13th, 2006.

About Sirtuins

Sirtuins are a recently discovered family of enzymes that promote normal cellular function. In particular, sirtuins improve the function of mitochondria which generate energy in cells. When organisms face adversity, sirtuins are activated as part of a natural process that maintains healthy function.

Therefore, sirtuins are attractive drug targets which may be therapeutically beneficial for diseases in which mitochondria are dysfunctional, often observed in diseases of aging. These diseases include metabolic diseases such as Type 2 Diabetes, neurological diseases, and other mitochondrial disorders. Sirtuin therapeutics offer the potential for a novel class of drugs that can treat significant diseases of aging in a new way.

About Sirtris Pharmaceuticals

Sirtris Pharmaceuticals is a biopharmaceutical company developing novel therapeutics that modulate sirtuins. Sirtris has the dominant sirtuin intellectual property estate and know-how with a comprehensive suite of reagents, proprietary assays, transgenic animal models, and biomarkers. Sirtris is building a robust pipeline of therapeutics for diseases of aging in the areas of metabolic and neurological diseases.

Sirtris Pharmaceuticals was founded in 2004 by Rich Aldrich, Richard Pops, Paul Schimmel, David Sinclair and Christoph Westphal and has raised a total of $82 million since inception from investors including: Polaris Venture Partners, TVM Capital, Cardinal Partners, Skyline Ventures, Three Arch Partners, The Wellcome Trust, Bessemer Venture Partners, Novartis Bioventures Fund, Cargill Ventures, Genzyme Ventures, QVT Fund LP, Cycad Group, Hunt Ventures, Red Abbey, and Alexandria Equities, LLC. The company’s headquarters are in Cambridge, Massachusetts. For additional information, please visit http://www.sirtrispharma.com.